That is the topic of a recent BioSpace article titled “How Effective Will TrumpRx and Other Direct-to-Consumer Drug Pricing Initiatives Be?” A am quoted in the article as follows:
While [direct-to-consumer] DTC has been a growing trend in biopharma for nearly two years now—Lilly launched LillyDirect in January 2024—the number of drugmakers looking to sell their products directly to patients has spiked in recent months.
Drug pricing is a delicate issue and pharmas have long been under pressure to improve access to medicines. “The goal of drug pricing is to set them high enough so pharmaceutical companies are incentivized to fund the research and development needed to bring new drugs to the market,” Jason Shafrin, senior managing director of the Center for Healthcare Economics & Policy at FTI Consulting, told BioSpace in an email.
On the flipside, drugs must be priced “so that the benefit to society outweighs the cost,” he added.
On both counts, Shafrin, along with other experts that spoke to BioSpace for this piece, questioned the effectiveness of the DTC approach.
You can read the full article here.
Disclaimer :
This article is solely for informational purposes, any medical information contained is not a substitute for professional medical advice and readers should not rely on it as such.
If you believe there may be errors or misinformation in this article, we encourage you to contact the webmasters by messaging the provided contact information.
Your feedback is valuable, and we are committed to rectifying any inaccuracies. Please note that the content will be re-evaluated, and corrections will be made as necessary following your submission.